AbbVie Reports Positive Topline Phase 3 Results for Lutikizumab in Moderate to Severe Hidradenitis Suppurativa

AbbVie has announced positive topline results from its Phase 3 INTREPID study, evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin (IL) 1α/1β antagonist, for adults and adolescents with moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint, showing significantly higher response rates for HiSCR75 at Week 16 compared to placebo. Lutikizumab also demonstrated statistically significant improvements in HS-related skin pain and a reduction in disease flares, indicating a potential new treatment option for this chronic inflammatory skin condition.